Paralel Advisors and
Versor Investments adjust positions in
Leidos Holdings, contributing to all-time high stock performances. This, coupled with
Leidos' strong and continuous growth, in light of its P/E ratio, justifies analysts’ bullish attitudes towards the bio-tech company.
National Bank of Canada and
Victory Capital Management further bolster their positions, while
Pzena Investment Management reduces theirs significantly.
Leidos outperforms the 200-Day moving average, reflecting positive market trends. Moreover, recent
contracts secured, such as the CDC's National Health Safety Network modernization contract and a $738M cybersecurity support deal, underscore the company's momentum. Despite these successes,
Director Gary May and other insiders sell a significant amount of stock. Analysts, however, have increased Leidos'
price target to $175. Even with these developments, the company faces challenges in a competitive landscape.
Leidos Holdings LDOS News Analytics from Fri, 29 Dec 2023 08:00:00 GMT to Sun, 08 Sep 2024 15:00:08 GMT -
Rating 7
- Innovation 2
- Information 8
- Rumor -6
